Abbott: Spin-Off Speculation Adds Optionality, But Valuation and Execution Risks Keep WAIT Intact

What happened

Abbott shares have been range-bound after the company lowered fiscal 2026 guidance amid softer electrophysiology and continuous glucose monitor demand, a development that tempers the device-led growth story highlighted in the prior thesis. A Seeking Alpha article argues the market has already priced in these headwinds plus litigation overhang, and that a potential spin-off of the nutrition business could unlock value by sharpening the remaining MedTech/Diagnostics/Pharma portfolio and creating a new S&P 500-eligible entity. The master report, however, still rates Abbott WAIT at $107, with limited margin of safety: trailing P/E near 34x and EV/EBITDA near 18.6x are not cheap, and the company still faces Libre FDA quality remediation, Exact Sciences dilution through 2027, and persistent nutrition volume declines. The article's claimed 18.8x P/E appears to be a forward or adjusted measure, and the spin-off is speculative with no announced timetable from management, so the bullish entry-point argument should be viewed with skepticism. Net-net, the new information adds a potential structural catalyst but does not resolve the near-term execution risks that justify staying on the sidelines until either valuation improves toward $98 or device and FDA updates turn definitively positive.

Implication

Investors should treat the nutrition spin-off as an unconfirmed option, not a base-case catalyst; only add exposure if Abbott formally announces a separation with clear capital-allocation and S&P inclusion steps. The current price of $107 is above the master report's attractive entry of $98, and the trailing P/E of 34.5x leaves little room for error if EP/CGM headwinds extend into 2027. The next 90 days are critical: watch for medical device growth holding above 8%, Libre remediation updates from FDA, and any sequential stabilization in nutrition volumes. If those checkpoints fail, the bear scenario of $95 becomes more likely; if they succeed and the spin-off is confirmed, the bull case of $125 gains credibility. Position sizing should remain modest, favoring a re-entry near $98 or after a decisive break above $118 with confirmation, rather than relying on a single bullish article's double-digit upside claim.

Thesis delta

The new article introduces a nutrition spin-off as a potential upside catalyst that was not part of the prior thesis, but it does not change the fundamental risk/reward at $107. Demand headwinds in EP/CGM and litigation overhang are real, and the claimed 18.8x P/E is inconsistent with the trailing 34.5x in the master report. The thesis remains WAIT, with no change to the $98 attractive entry or $118 trim level until management action or operational data improves.